LEVERAGE LONG - MODERNA | Market Closed - Euronext Paris 12:30:01 2024-05-08 pm EDT | ||
| 8.6 EUR | +3.74% |
|
| Current month | +15.28% | ||
| 1 month | +32.51% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
More news
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-08 | 8.6 | +3.74% | 78 |
| 24-05-07 | 8.29 | -1.54% | 79 |
| 24-05-06 | 8.42 | -4.97% | 91 |
| 24-05-03 | 8.86 | +1.49% | 9 |
| 24-05-02 | 8.73 | +17.02% | 94 |
Real-time Euronext Paris
Last update May 08, 2024 at 12:30 pm EDT
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | 
Société Générale
|
| 12Z4S | |
| ISIN | DE000SD46UM7 |
| Date issued | 2021-04-01 |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 42.74 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 525.3 € |
|---|---|
| Lowest since issue | 2.834 € |
| Spread | 0.04 € |
| Spread % | 0.46% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
121.9
USD
Average target price
138.7
USD
Spread / Average Target
+13.77%
- Stock Market
- Certificates
- 12Z4S Certificat